Clinical trials: Eisenmenger Syndrome
Eisenmenger Complex, Pulmonary Hypertension
Six Minutes Walk Test and Shuttle Walk Test in Eisenmenger Syndrome
The purpose of this study is to verify the applicability Six minutes walk test and Shuttle walk test in assessing functional capacity in patients with Eisenmenger Syndrome.
- Conditions
- Eisenmenger Complex, Pulmonary Hypertension, Congenital Heart Defects
- Trial name
- NCT02752399
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Federal University of São Paulo
Pulmonary Arterial Hypertension
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology).
- Trial name
- NCT00367770
- Testing
- Tracleer®
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 37 people
- Sponsor
- Actelion
Eisenmenger Syndrome
Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
A growing body of data, suggests that transcatheter valves are effective when implanted in other locations (mitral, aortic, tricuspid) and in high pressure environments.
- Trial name
- NCT02119442
- Testing
- Transcather Valve Implantation
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of California, Los Angeles
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular…
- Trial name
- SuMILE (NCT07356778)
- Testing
- Sotatercept, vasodilator-based PAH therapy
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Kazuya Hosokawa
Eisenmenger Complex
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome
In this study, the investigator will evaluate the treatment effects and safety, patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan.
- Trial name
- NCT04732650
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Congenital Heart Disease (CHD), Eisenmenger Syndrome
Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome
The present study seeks to provide pilot data on the safety and efficacy of medical therapy with sotatercept in patients with an established diagnosis of congenital heart disease and Eisenmenger syndrome.
- Conditions
- Congenital Heart Disease (CHD), Eisenmenger Syndrome, PAH
- Trial name
- CHASE (NCT07498803)
- Testing
- Sotatercept
- Volunteers
- 40 people
- Sponsor
- Philipps University Marburg
Eisenmenger Complex, Hypertension, Pulmonary
Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome
The purpose of this study was to evaluate the acute effects of oxygen supplementation during a submaximal exercise test in patients with Eisenmenger's Syndrome.
- Trial name
- NCT02661802
- Testing
- Oxygen Supplementation
- Volunteers
- 30 people
- Sponsor
- Federal University of São Paulo
Pulmonary Arterial Hypertension (PAH)
Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients
Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that constitutes a great burden at the individual as well as the familial and social level.
- Trial name
- NCT00586794
- Testing
- Sildenafil
- Where
- 20 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Competence Network for Congenital Heart Defects
Eisenmenger Syndrome
Eisenmenger Syndrome in the Nordic Countries
This is a historical cohort study with retrospective collection of data comprising all Nordic patient's diagnosed with Eisenmengers syndrome in the period 1977 through 2011.
- Trial name
- NCT01976533
- Where
- 4 sites in Denmark, Finland and 2 more
- Volunteers
- 714 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pulmonary Arterial Hypertension, Eisenmenger Syndrome
Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects
The purpose of this study is to investigate the influence of physical training on exercise capacity, quality of life, functional class, oxygen consumption and right ventricular function in patients with severe associated…
- Trial name
- NCT01397110
- Testing
- respiratory and exercise therapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.
- Trial name
- MAESTRO-OL (NCT01739400)
- Testing
- Macitentan 10 mg tablet, once daily.
- Where
- 51 sites in United States, Austria and 17 more
- Volunteers
- 217 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
COMPERA / COMPERA-KIDS
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for…
- Trial name
- COMPERA (NCT01347216)
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 14,000 people
- Sponsor
- Technische Universität Dresden
Pulmonary Arterial Hypertension, Congenital Heart Disease
Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is common in patients with congenital heart disease.
- Conditions
- Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome
- Trial name
- NCT01319045
- Testing
- Iloprost
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Los Angeles
Pulmonary Arterial Hypertension
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.
- Trial name
- MAESTRO (NCT01743001)
- Testing
- Macitentan 10 mg
- Where
- 55 sites in United States, Austria and 19 more
- Volunteers
- 226 people
- Sponsor
- Actelion
Eisenmenger's Syndrome
The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome
Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's…
- Trial name
- NCT01283958
- Volunteers
- 12 people
- Sponsor
- Gachon University Gil Medical Center
Congenital Heart Disease, Pulmonary Arterial Hypertension
4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart Disease
Congenital heart disease is the most common congenital anomaly. The life expectancy of children with congenital heart disease has increased considerably in recent years.
- Trial name
- 4DFlowHTAPCC (NCT03928002)
- Testing
- 4D Flow magnetic resonance imagery, Cardiac catheterization
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Arterial Hypertension
Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease
The prevalence of PAH associated with congenital systemic-to-pulmonary shunts in Western countries has been estimated to range between 1.6 and 12.5 cases per million adults, with 25-50% of this population affected by…
- Trial name
- EIGER (NCT01383083)
- Volunteers
- 42 people
- Sponsor
- Maryknoll Medical Center
Congenital Disorders
Eisenmenger's Syndrome in Adults With CHD
Review the outcome of treatment with endothelin receptor antagonists (bosentan or sitaxsetan) alone or in combination with Sildenafil (a PDE-5 inhibitor) in adult patients with pulmonary hypertension due to congenital heart…
- Trial name
- NCT00266903
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Children's Healthcare of Atlanta
Eisenmenger Syndrome
Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome
A preliminary observational study by the investigators has shown that tadalafil, a selective phosphodiesterase-5 inhibitor (PDE-5) decreases pulmonary vascular resistance(PVR) in patients of eisenmenger syndrome (ES) resulting in…
- Trial name
- NCT01200732
- Where
- India
- Volunteers
- 28 people
- Sponsor
- Govind Ballabh Pant Hospital